Correlations between FEV1 and patient-reported outcomes: A pooled analysis of 23 clinical trials in patients with chronic obstructive pulmonary disease

Pulmonary Pharmacology and Therapeutics

Volumn 49, Issue , 2018, Pages 11-19

  Donohue, James F ^a   Jones, Paul W ^b   Bartels, Christian ^c   Marvel, Jessica ^c   D'Andrea, Peter ^c   Banerji, Donald ^c   Morris, David G ^c   Patalano, Francesco ^c   Fogel, Robert ^c  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b ST GEORGE S HOSPITAL   (United Kingdom)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

COPD; FEV1; PROs; Regression modelling; SGRQ; TDI

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; FORMOTEROL; GLYCOPYRRONIUM; GLYCOPYRRONIUM BROMIDE PLUS INDACATEROL; INDACATEROL; MUSCARINIC RECEPTOR BLOCKING AGENT; SALMETEROL; TIOTROPIUM BROMIDE; BRONCHODILATING AGENT;

ADULT; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PATIENT-REPORTED OUTCOME; PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCORING SYSTEM; ST. GEORGE RESPIRATORY QUESTIONNAIRE; TRANSITION DYSPNEA INDEX; LUNG FUNCTION TEST; META ANALYSIS; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX;

BRONCHODILATOR AGENTS; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; PATIENT REPORTED OUTCOME MEASURES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATORY FUNCTION TESTS; SEVERITY OF ILLNESS INDEX;

EID: 85042881309     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2017.12.005     Document Type: Review

References (51)

1. Baloira, A., Which is the optimal bronchodilator therapy for chronic obstructive pulmonary disease?. Expet Rev. Respir. Med. 7 (2013), 17–24.
2. Global Initiative for Chronic Obstructive Lung Disease (GOLD): Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. [http://www.goldcopd.com].
3. Tashkin, D.P., Ferguson, G.T., Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease. Respir. Res., 14, 2013, 49.
4. Price, D., Yawn, B., Brusselle, G., Rossi, A., Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD. Prim. Care Respir. J. 22 (2013), 92–100.
5. Suissa, S., McGhan, R., Niewoehner, D., Make, B., Inhaled corticosteroids in chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 4 (2007), 535–542.
6. Jones, P.W., Agusti, A.G., Outcomes and markers in the assessment of chronic obstructive pulmonary disease. Eur. Respir. J. 27 (2006), 822–832.
7. Jones, P.W., Health status measurement in chronic obstructive pulmonary disease. Thorax 56 (2001), 880–887.
8. Lavorini, F., Quantifying bronchodilator responses in chronic obstructive pulmonary disease trials. Br. J. Clin. Pharmacol. 59 (2005), 385–386.
9. Chronic Obstructive Pulmonary Disease, Developing drugs for treatment guidelines for industry. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm.
10. Jones, P.W., Health status: what does it mean for payers and patients?. Proc. Am. Thorac. Soc. 3 (2006), 222–226.
11. Jones, P.W., Beeh, K.M., Chapman, K.R., Decramer, M., Mahler, D.A., Wedzicha, J.A., Minimal clinically important differences in pharmacological trials. Am. J. Respir. Crit. Care Med. 189 (2014), 250–255.
12. Young, R.P., Hopkins, R., Eaton, T.E., Forced expiratory volume in one second: not just a lung function test but a marker of premature death from all causes. Eur. Respir. J. 30 (2007), 616–622.
13. Westwood, M., Bourbeau, J., Jones, P.W., Cerulli, A., Capkun-Niggli, G., Worthy, G., Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review. Respir. Res., 12, 2011, 40.
14. Aaron, S.D., Vandemheen, K.L., Fergusson, D., Maltais, F., Bourbeau, J., Goldstein, R., Balter, M., O'Donnell, D., McIvor, A., Sharma, S., et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann. Intern. Med. 146 (2007), 545–555.
15. Vogelmeier, C., Kardos, P., Harari, S., Gans, S.J., Stenglein, S., Thirlwell, J., Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study. Respir. Med. 102 (2008), 1511–1520.
16. Tashkin, D.P., Pearle, J., Iezzoni, D., Varghese, S.T., Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD 6 (2009), 17–25.
17. Jones, P.W., Donohue, J.F., Nedelman, J., Pascoe, S., Pinault, G., Lassen, C., Correlating changes in lung function with patient outcomes in chronic obstructive pulmonary disease: a pooled analysis. Respir. Res., 12, 2011, 161.
18. Miller, M.R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C.P., Gustafsson, P., et al. Standardisation of spirometry. Eur. Respir. J. 26 (2005), 319–338.
19. Jones, P.W., St. George's respiratory Questionnaire: MCID. COPD 2 (2005), 75–79.
20. Mahler, D.A., Witek, T.J., The MCID of the transition dyspnea index is a total score of one unit. COPD 2 (2005), 99–103.
21. Bates, D., Maechler, M., Bolker, B.M., Walker, S., Fitting linear mixed-effects models using lme4. J. Stat. Software 67 (2015), 1–48.
22. Bates, D., Maechler, M., Bolker, B.M., Walker, S., Linear Mixed-effects Models using Eigen and S4 R Package. 2015.
23. Least-Squares Means R package [http://CRAN.R-project.org/package=lsmeans].
24. Frost, J.R., Correcting for regression dilution bias: comparison of methods for a single predictor variable. JR. Stat. Soc. A 163 (2000), 173–189.
25. Watson, L., Schouten, J.P., Lofdahl, C.G., Pride, N.B., Laitinen, L.A., Postma, D.S., Predictors of COPD symptoms: does the sex of the patient matter?. Eur. Respir. J. 28 (2006), 311–318.
26. Van de Maele, B., Fabbri, L.M., Martin, C., Horton, R., Dolker, M., Overend, T., Cardiovascular safety of QVA149, a combination of Indacaterol and NVA237, in COPD patients. COPD 7 (2010), 418–427.
27. van Noord, J.A., Buhl, R., Laforce, C., Martin, C., Jones, F., Dolker, M., Overend, T., QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease. Thorax 65 (2010), 1086–1091.
28. Bateman, E.D., Ferguson, G.T., Barnes, N., Gallagher, N., Green, Y., Henley, M., Banerji, D., Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur. Respir. J. 42 (2013), 1484–1494.
29. Dahl, R., Chapman, K.R., Rudolf, M., Mehta, R., Kho, P., Alagappan, V.K., Chen, H., Banerji, D., Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study. Respir. Med. 107 (2013), 1558–1567.
30. Vogelmeier, C.F., Bateman, E.D., Pallante, J., Alagappan, V.K., D'Andrea, P., Chen, H., Banerji, D., Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir. Med. 1 (2013), 51–60.
31. Decramer, M.L., Chapman, K.R., Dahl, R., Frith, P., Devouassoux, G., Fritscher, C., Cameron, R., Shoaib, M., Lawrence, D., Young, D., McBryan, D., Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. Lancet Respir. Med. 1 (2013), 524–533.
32. Cope, S., Donohue, J.F., Jansen, J.P., Kraemer, M., Capkun-Niggli, G., Baldwin, M., Buckley, F., Ellis, A., Jones, P., Comparative efficacy of long-acting bronchodilators for COPD: a network meta-analysis. Respir. Res., 14, 2013, 100.
33. Spina, D., Pharmacology of novel treatments for COPD: are fixed dose combination LABA/LAMA synergistic?. Eur. Clin. Respir. J., 2015, 2.
34. Dahl, R., Chung, K.F., Buhl, R., Magnussen, H., Nonikov, V., Jack, D., Bleasdale, P., Owen, R., Higgins, M., Kramer, B., Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax 65 (2010), 473–479.
35. Feldman, G., Siler, T., Prasad, N., Jack, D., Piggott, S., Owen, R., Higgins, M., Kramer, B., Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week study. BMC Pulm. Med., 10, 2010, 11.
36. D'Urzo, A., Ferguson, G.T., van Noord, J.A., Hirata, K., Martin, C., Horton, R., Lu, Y., Banerji, D., Overend, T., Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir. Res., 12, 2011, 156.
37. Donohue, J.F., Fogarty, C., Lotvall, J., Mahler, D.A., Worth, H., Yorgancioglu, A., Iqbal, A., Swales, J., Owen, R., Higgins, M., Kramer, B., Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am. J. Respir. Crit. Care Med. 182 (2010), 155–162.
38. Chapman, K.R., Rennard, S.I., Dogra, A., Owen, R., Lassen, C., Kramer, B., Long-term safety and efficacy of indacaterol, a long-acting beta(2)-agonist, in subjects with COPD: a randomized, placebo-controlled study. Chest 140 (2011), 68–75.
39. Korn, S., Kerwin, E., Atis, S., Amos, C., Owen, R., Lassen, C., Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week study. Respir. Med. 105 (2011), 719–726.
40. Buhl, R., Dunn, L.J., Disdier, C., Lassen, C., Amos, C., Henley, M., Kramer, B., Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD. Eur. Respir. J. 38 (2011), 797–803.
41. Kerwin, E.M., Gotfried, M.H., Lawrence, D., Lassen, C., Kramer, B., Efficacy and tolerability of indacaterol 75 mug once daily in patients aged >/=40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies. Clin Ther. 33 (2011), 1974–1984.
42. Gotfried, M.H., Kerwin, E.M., Lawrence, D., Lassen, C., Kramer, B., Efficacy of indacaterol 75 mug once-daily on dyspnea and health status: results of two double-blind, placebo-controlled 12-week studies. COPD 9 (2012), 629–636.
43. Kornmann, O., Dahl, R., Centanni, S., Dogra, A., Owen, R., Lassen, C., Kramer, B., Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur. Respir. J. 37 (2011), 273–279.
44. Kinoshita, M., Lee, S.H., Hang, L.W., Ichinose, M., Hosoe, M., Okino, N., Prasad, N., Kramer, B., Fukuchi, Y., Efficacy and safety of indacaterol 150 and 300 microg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: a 12-week, placebo-controlled study. Respirology 17 (2012), 379–389.
45. Kerwin, E., Hebert, J., Gallagher, N., Martin, C., Overend, T., Alagappan, V.K., Lu, Y., Banerji, D., Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur. Respir. J. 40 (2012), 1106–1114.
46. Wedzicha, J.A., Decramer, M., Ficker, J.H., Niewoehner, D.E., Sandstrom, T., Taylor, A.F., D'Andrea, P., Arrasate, C., Chen, H., Banerji, D., Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir. Med. 1 (2013), 199–209.
47. Chapman, K.R., Beeh, K.M., Beier, J., Bateman, E.D., D'Urzo, A., Nutbrown, R., Henley, M., Chen, H., Overend, T., D'Andrea, P., A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study. BMC Pulm. Med., 14, 2014, 4.
48. Vincken, W., Aumann, J., Chen, H., Henley, M., McBryan, D., Goyal, P., Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study. Int. J. Chronic Obstr. Pulm. Dis. 9 (2014), 215–228.
49. Yao, W., Wang, C., Zhong, N., Han, X., Wu, C., Yan, X., Chen, P., Yang, W., Henley, M., Kramer, B., Effect of once-daily indacaterol in a predominantly Chinese population with chronic obstructive pulmonary disease: a 26-week Asia-Pacific study. Respirology 19 (2014), 231–238.
50. Wang, C., Sun, T., Huang, Y., Humphries, M., Bai, L., Li, L., Wang, Q., Kho, P., Firth, R., D'Andrea, P., Efficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 study. Int. J. Chronic Obstr. Pulm. Dis. 10 (2015), 57–68.
51. Mahler, D.A., Kerwin, E., Ayers, T., FowlerTaylor, A., Maitra, S., Thach, C., Lloyd, M., Patalano, F., Banerji, D., FLIGHT1 and FLIGHT2: efficacy and safety of QVA149 (Indacaterol/Glycopyrrolate) versus its monocomponents and placebo in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 192 (2015), 1068–1079.